Combination of Metformin With Gefitinib to Treat NSCLC

Phase 2 Completed 224 enrolled Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether metformin in combination with gefitinib are effective in patients with previously untreated advanced or metastatic Non-Small-Cell Lung cancer with epidermal growth factor receptor (EGFR) mutations

Timeline

Start: 2013-05
Primary completion: 2017-12
Completion: 2018-06-04

Publications

Li KL, Li L, Zhang P, Kang J, Wang YB, Chen HY, He Y. A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 May;18(3):340-343. doi: 10.1016/j.cllc.2016.12.003. Epub 2016 Dec 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	1000 mg	Oral
Background	Gefitinib	Small molecule	250 mg	—

Combination of Metformin With Gefitinib to Treat NSCLC

Summary

Timeline

Publications

Drugs

Indications